The visionary structure of the Institute, as well as the generous support of the Robert A. and Renee E. Belfer Foundation and the institute’s donors, enable the Belfer Institute to integrate its scientific teams, access cancer models and leverage a broad range of leading edge research capabilities, giving the Institute a direct line of sight from the cancer genome to patient treatment.
The following donors have generously supported the Belfer Institute for Applied Cancer Science by making gifts totaling $100,000 or more.
Aid for Cancer Research
The Arthur & Rochelle Belfer Foundation, Inc.
The Robert A. & Renée E. Belfer Family Foundation
Irene E. & George A. Davis Foundation
Mary E. Davis
Expect Miracles Foundation
Flight Attendant Medical Research Institute
Marion Huber Trust
The Estate of Lily I. Jutila
Geraldine C.∞ & Bennett S. LeBow
Mutual Funds Against Cancer Golf Classic
The Smolokowski Family
∞ denotes deceased individuals
In the News
Dr. Cloud Paweletz's publication - "Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA" - cited in Oncology Times "Best Lung Cancer Research of 2014".
Molecular Cancer Research (MCR) editorial group has selected a Belfer publication - “Evaluating TBK1 as a Therapeutic Target in Cancers with Activated IRF3” - to be reprinted in a 2014 Must-Read compilation for AACR.
Dr. P. Janne and Dr. C. Paweletz discuss an innovative approach for tumor genotyping and disease monitoring for targeted lung cancer therapies.
Belfer & Janssen announce collaboration on cancer immunotherapies for lung cancer
Phase I Study of Novel Third-Generation EGFR Inhibitor Holds Promise Against Resistance Mutation in Patients With Non–Small Cell Lung Cancer
Belfer scientists identified phospho-IRF3 as a biomarker of TBK1 activity in K-Ras mutant pancreatic cancer. TBK1 inhibition may have therapeutic potential in defined patient populations.
Poster presentation, PDx Platform of High Grade Serous Ovarian Cancer, at the 2014 AACR General Meeting in San Diego by Sangeetha Palakurthi PhD, Head of Cancer Biology and Pharmacology.